amyloid-β peptides

Edonerpic maleate (T-817 maleate) is a neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

(Rac)-Z-Phe-Phe-FMK (Cathepsin L-IN-2) is a cathepsin L inhibitor that inhibits the tendency of β-amyloid to induce apoptotic changes .

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Amyloid β Peptide (42-1)(human) acetate is the inactive form of Amyloid β Peptide (1-42). Amyloid β Peptide (42-1)(human) acetate is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

V-9-M Cholecystokinin nonapeptide (Prepro CCK Fragment V-9-M) is a precursor compound of cholecystokinin (CCK). Cholecystokinin (CCK) is a brain-intestinal peptide that stimulates gallbladder contraction and pancreatic exocrine. It can be extracted from the small intestine of dogs and cats and can cause gallbladder contraction.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

Dihydroergocristine mesylate (DHEC (mesylate))(DHEC mesylate) is the methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. Dihydroergocristine mesylate is a inhibitor of γ-secretase (GSI), , reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1]. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. It has a role as a vasodilator agent, an alpha-adrenergic antagonist and a geroprotector. It contains a dihydroergocristine.

BuChE-IN-20 is a selective hBuChE inhibitor (IC50= 0.13 μM) with the ability to cross the blood-brain barrier (BBB). This compound, a derivative of L-Tryptophan, exhibits neuroprotective effects by inhibiting nitric oxide (NO) production and reducing reactive oxygen species (ROS) levels. It effectively suppresses the self-aggregation of amyloid-beta (Aβ) peptides and is applicable in Alzheimer's disease research.

BSBM6 is an inhibitor of Aβ aggregation and neuronal toxicity that acts by reversing the aggregation and toxicity of amyloid-β peptides.

BMS-984923 is an orally available and blood-brain barrier permeable mGluR5 silencing allosteric modulator that inhibits β-amyloid oligomer-induced aberrant synaptic signaling, and can be used to study Alzheimer's disease.

Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and functions as an efficient, non-competitive, long-acting, and selective inhibitor of acetylcholinesterase (AChE). This compound reduces the formation of amyloid precursor protein (APP) and β-amyloid peptides (Aβ), potentially improving cognitive abilities and alleviating the progression of Alzheimers disease.

β-Amyloid (29-40) is a fragment of Amyloid-β peptide. Alzheimer's beta amyloid peptide (29-40 42) C-terminal fragments exhibit physical and chemical properties similar to fusion peptides of viral proteins, inducing liposome fusion in vitro.